pipsqueak3 wrote: Agreed, and it ran on the preliminary rat data only. I too view the reward to risk very favourable, as downside risk realistically is around .30 and price could run pretty rampant, at least to the all time high, with even an inkling of human clinicals... the big question of everyone here is when will the human clinicals begin, as there has been a history of delays. IMO, the volume does tell a large story here. During the first run a few years ago to 1.39/share on the results of the breast cancer PDC testing, the stock was VERY thinly traded. On the TSX alone, excluding any ATS activity, it traded only 2.8 million shares during the entire second quarter of 2010. And, the dollar volume was only 1.8 million dollars, meaning most of that run was short lived and amplified by hysteria. Currently, beginning with Q4, 2013, the dollar volumes we have seen in each quarter since has been as follows:
Q4/13=$1.6m, Q1/14=$5.2m, Q2/14=$31.6m, Q3/14=$7.3m, Q4/14=$20.6m, Q1/15=$2.8m so far.
So, in my mind, if we let the money do the speaking, there never was any true belief or knowledge the TLT was doing any human clinicals back in 2010 and forward, as we obviously would have seen more institutional buying. This time however, we have seen very high dollar volumes right from the lows of .25/share, and it appears to me that the market is telling us that it does expect human clinicals in 2015 to move forward.
I appreciate many posts on here about the supplemental revenues from unit sales, the timelines, the science, the industry etc etc.. None of those should be taken for granted. During this time of uncertainty when timelines slip, I do put stock in volumes as they often speak louder than words.